Business Strategy
FXT’s mission is to create and advance to clinical proof of concept a portfolio of proprietary, first in class therapeutics in the area of inflammation, by leveraging FXT’s competencies in early stage development of drugs acting on the immune system and in functional based discovery.
FXT’s vision is to be recognized by the scientific, medical and investment community as a successful and innovative company in the area of inflammation. Our aim over the coming years is to realize the value of our IP through the achievement of positive clinical data with the lead BSCI FX125L and to create a diversified portfolio of products in the area of inflammation.
FXT intends to license-out its products to a suitable partner for development beyond the clinical proof of concept stage and partner some of its research-stage technologies to accelerate the commercial development of the company.